FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

R Reeja Raj (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) S Samanta Catueno (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) A Amber Gibson (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) D David McCall (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) M Miriam B. Garcia (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) C César Nunez (1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX) M Michael Roth (MD Anderson Cancer Center, Houston, Texas, United States) K Koji Sasaki (1The University of Texas MD Anderson Cancer Center, Houston, TX) P Priti Tewari (3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX) G Ghayas C. Issa A Aziz Farhat (2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX) J Jeremy Connors (3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX) I Irtiza Sheikh (3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX) Y Yuki Nishida J Joanna S. Yi (4Division of Pediatrics, Baylor College of Medicine, Houston, TX) A Alexandra M. Stevens A Alex Bataller (2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX) K Kapil Bhalla (2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX) D Demetrios Petropoulos (3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX) N Naval Daver (1The University of Texas MD Anderson Cancer Center, Houston, TX) T Tapan Kadia (2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX) B Branko Cuglievan C Courtney D. DiNardo (Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA)

Abstract

Abstract FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 21
Published November 20, 2025
Pages 2608-2611
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (23)

R

Reeja Raj

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

S

Samanta Catueno

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

A

Amber Gibson

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

D

David McCall

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

M

Miriam B. Garcia

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

C

César Nunez

1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

M

Michael Roth

MD Anderson Cancer Center, Houston, Texas, United States

K

Koji Sasaki

1The University of Texas MD Anderson Cancer Center, Houston, TX

P

Priti Tewari

3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

G

Ghayas C. Issa

A

Aziz Farhat

2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

J

Jeremy Connors

3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

I

Irtiza Sheikh

3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Y

Yuki Nishida

J

Joanna S. Yi

4Division of Pediatrics, Baylor College of Medicine, Houston, TX

A

Alexandra M. Stevens

A

Alex Bataller

2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

K

Kapil Bhalla

2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

D

Demetrios Petropoulos

3Division of Pediatrics, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

N

Naval Daver

1The University of Texas MD Anderson Cancer Center, Houston, TX

T

Tapan Kadia

2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

B

Branko Cuglievan

C

Courtney D. DiNardo

Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA